[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 2016

Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis

Author Affiliations
  • 1Albany Medical College, Albany, New York
  • 2Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut
JAMA Dermatol. 2016;152(4):492-493. doi:10.1001/jamadermatol.2015.3772

Nail dystrophy associated with alopecia areata (AA) and variants alopecia totalis and alopecia universalis (AU) may cause discomfort or pain and limitation of function. Currently, no reliably effective treatment options are available.1 The successful treatment of AA and variants with the oral Janus kinase (JAK) inhibitors tofacitinib, ruxolitinib, and baricitinib24 suggests the possibility that this class of agents may be a therapeutic option for nail dystrophy associated with AA.

First Page Preview View Large
First page PDF preview
First page PDF preview